In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Evidence in the field of CVD in pregnancy is sparse, but the condition remains a concern

ESC EURObservational Research Programme registry in Pregnancy and Heart Disease finds maternal mortality rates '100-times higher than normal'

Pregnancy and Cardiovascular Disease


Paris, France, 30 August: Pre-existing heart disease in pregnancy remains a concern. Complications are frequent and in some cases may be life-threatening for both the mother and her child. In Europe maternal heart disease has now become the major cause of maternal death during pregnancy.

As interim data from the ESC's special registry on pregnancy in cardiac disease suggests, the numbers of women at risk is not in decline, mainly because of today's older age at first pregnancy and with it a concomitant increase in risks of diabetes, hypertension and obesity.

Professor Jolien Roos-Hesselink, joint chairman of the ESC registry together with Professor Roger Hall (Norwich, UK), reported that the most frequently diagnosed condition in the registry population was congenital heart disease, found in around 60% of subjects. More than 1300 women have been enrolled into the registry so far - from 28 countries and 60 centres; they consist of 869 women with congenital heart disease, 333 with valvular heart disease patients, 79 with cardiomyopathy and 24 with ischaemic heart disease.

Professor Roos-Hesselink said that evidence in this field is sparse, with randomised trials impossible to perform: "So the only way to improve our knowledge of the factors which determine outcome in pregnant women with heart disease is to gather data on a large number of pregnancies and try to find patterns of outcome which correlate with management strategies. In this way we might determine the areas of danger for both mother and child  and the best forms of treatment."

It was because of the need to generate relevant data in areas such as this, that the concept of European registries was developed in 2006. Data collection in the pregnancy and CVD registry began in 2008, with information recorded on CVD diagnosis, medication, cardiac complications, obstetric complications, and pregnancy outcome at six months.

An interim analysis of these pregnancies was presented at the ESC Congress but, said Professor Roos-Hesselink, data collection continues and it is clear larger numbers will be required to obtain meaningful conclusions.

However, results so far reflect a very high hospitalisation rate during pregnancy: 338 patients (26% of all pregnancies) were hospitalised, 203 of cardiac cause. Maternal death occurred in 13 patients (1%) and fetal death in 59 cases (4.5%). These death rates, said Professor Roos-Hesselink, are significantly higher than normal; maternal mortality is in the order of 100 times higher and fetal mortality 10 times higher. There was also a high rate of delivery by Caesarean section of around 40%.

She added that no single cause for the high mortality rate is as yet clear, but the further analysis and larger numbers of the study should provide stringer evidence. "We are analysing patterns of therapy as well trying to identify the particular underlying cardiac conditions associated with mortality," she said.

References

This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2011.
Pregnancy and Heart disease pilot study
The press release has been written by the investigator and edited by the ESC.

Notes to editor

About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 68,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.

About ESC Congress 2011
ESC Congress 2011 will take place from 27 to 31 August at the Parc des Expositions - Paris Nord Villepinte, France. Information on the scientific programme is available here. More information on ESC Congress 2011 is available from the ESC Press Office or contact us at press@escardio.org